Parkinson Disease Drug Industry Research Report 2025

Summary

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

According to APO Research, The global Parkinson Disease Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Parkinson Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Parkinson Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Parkinson Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Parkinson Disease Drug include Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma and Astellas Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Parkinson Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinson Disease Drug.
The Parkinson Disease Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Parkinson Disease Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Parkinson Disease Drug Segment by Company

Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
F.Hoffmann-La Roche
H.Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Bausch Health
Parkinson Disease Drug Segment by Type

Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other
Parkinson Disease Drug Segment by Application

Under 40 Years Old
40-65 Years Old
Above 65 Years Old
Parkinson Disease Drug Segment by Application

Under 40 Years Old
40-65 Years Old
Above 65 Years Old
Parkinson Disease Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parkinson Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Parkinson Disease Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Parkinson Disease Drug by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Sinemet-CR
2.2.3 Trastal
2.2.4 Madopar
2.2.5 COMT Inhibitor
2.2.6 Other
2.3 Parkinson Disease Drug by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Under 40 Years Old
2.3.3 40-65 Years Old
2.3.4 Above 65 Years Old
2.4 Assumptions and Limitations
3 Parkinson Disease Drug Breakdown Data by Type
3.1 Global Parkinson Disease Drug Historic Market Size by Type (2020-2025)
3.2 Global Parkinson Disease Drug Forecasted Market Size by Type (2026-2031)
4 Parkinson Disease Drug Breakdown Data by Application
4.1 Global Parkinson Disease Drug Historic Market Size by Application (2020-2025)
4.2 Global Parkinson Disease Drug Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Parkinson Disease Drug Market Perspective (2020-2031)
5.2 Global Parkinson Disease Drug Growth Trends by Region
5.2.1 Global Parkinson Disease Drug Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Parkinson Disease Drug Historic Market Size by Region (2020-2025)
5.2.3 Parkinson Disease Drug Forecasted Market Size by Region (2026-2031)
5.3 Parkinson Disease Drug Market Dynamics
5.3.1 Parkinson Disease Drug Industry Trends
5.3.2 Parkinson Disease Drug Market Drivers
5.3.3 Parkinson Disease Drug Market Challenges
5.3.4 Parkinson Disease Drug Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Parkinson Disease Drug Players by Revenue
6.1.1 Global Top Parkinson Disease Drug Players by Revenue (2020-2025)
6.1.2 Global Parkinson Disease Drug Revenue Market Share by Players (2020-2025)
6.2 Global Parkinson Disease Drug Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Parkinson Disease Drug Head Office and Area Served
6.4 Global Parkinson Disease Drug Players, Product Type & Application
6.5 Global Parkinson Disease Drug Manufacturers Established Date
6.6 Global Parkinson Disease Drug Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Parkinson Disease Drug Market Size (2020-2031)
7.2 North America Parkinson Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Parkinson Disease Drug Market Size by Country (2020-2025)
7.4 North America Parkinson Disease Drug Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Parkinson Disease Drug Market Size (2020-2031)
8.2 Europe Parkinson Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Parkinson Disease Drug Market Size by Country (2020-2025)
8.4 Europe Parkinson Disease Drug Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Parkinson Disease Drug Market Size (2020-2031)
9.2 Asia-Pacific Parkinson Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Parkinson Disease Drug Market Size by Country (2020-2025)
9.4 Asia-Pacific Parkinson Disease Drug Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Parkinson Disease Drug Market Size (2020-2031)
10.2 South America Parkinson Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Parkinson Disease Drug Market Size by Country (2020-2025)
10.4 South America Parkinson Disease Drug Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Parkinson Disease Drug Market Size (2020-2031)
11.2 Middle East & Africa Parkinson Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Parkinson Disease Drug Market Size by Country (2020-2025)
11.4 Middle East & Africa Parkinson Disease Drug Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Merck
12.1.1 Merck Company Information
12.1.2 Merck Business Overview
12.1.3 Merck Revenue in Parkinson Disease Drug Business (2020-2025)
12.1.4 Merck Parkinson Disease Drug Product Portfolio
12.1.5 Merck Recent Developments
12.2 Akorn
12.2.1 Akorn Company Information
12.2.2 Akorn Business Overview
12.2.3 Akorn Revenue in Parkinson Disease Drug Business (2020-2025)
12.2.4 Akorn Parkinson Disease Drug Product Portfolio
12.2.5 Akorn Recent Developments
12.3 GSK
12.3.1 GSK Company Information
12.3.2 GSK Business Overview
12.3.3 GSK Revenue in Parkinson Disease Drug Business (2020-2025)
12.3.4 GSK Parkinson Disease Drug Product Portfolio
12.3.5 GSK Recent Developments
12.4 Novartis
12.4.1 Novartis Company Information
12.4.2 Novartis Business Overview
12.4.3 Novartis Revenue in Parkinson Disease Drug Business (2020-2025)
12.4.4 Novartis Parkinson Disease Drug Product Portfolio
12.4.5 Novartis Recent Developments
12.5 Boehringer Ingelheim
12.5.1 Boehringer Ingelheim Company Information
12.5.2 Boehringer Ingelheim Business Overview
12.5.3 Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2020-2025)
12.5.4 Boehringer Ingelheim Parkinson Disease Drug Product Portfolio
12.5.5 Boehringer Ingelheim Recent Developments
12.6 Teva Pharmaceutical
12.6.1 Teva Pharmaceutical Company Information
12.6.2 Teva Pharmaceutical Business Overview
12.6.3 Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2020-2025)
12.6.4 Teva Pharmaceutical Parkinson Disease Drug Product Portfolio
12.6.5 Teva Pharmaceutical Recent Developments
12.7 Abbvie
12.7.1 Abbvie Company Information
12.7.2 Abbvie Business Overview
12.7.3 Abbvie Revenue in Parkinson Disease Drug Business (2020-2025)
12.7.4 Abbvie Parkinson Disease Drug Product Portfolio
12.7.5 Abbvie Recent Developments
12.8 Kyowa Hakko Kirin Pharma
12.8.1 Kyowa Hakko Kirin Pharma Company Information
12.8.2 Kyowa Hakko Kirin Pharma Business Overview
12.8.3 Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2020-2025)
12.8.4 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio
12.8.5 Kyowa Hakko Kirin Pharma Recent Developments
12.9 Astellas Pharma
12.9.1 Astellas Pharma Company Information
12.9.2 Astellas Pharma Business Overview
12.9.3 Astellas Pharma Revenue in Parkinson Disease Drug Business (2020-2025)
12.9.4 Astellas Pharma Parkinson Disease Drug Product Portfolio
12.9.5 Astellas Pharma Recent Developments
12.10 Desitin Arzneimittel
12.10.1 Desitin Arzneimittel Company Information
12.10.2 Desitin Arzneimittel Business Overview
12.10.3 Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2020-2025)
12.10.4 Desitin Arzneimittel Parkinson Disease Drug Product Portfolio
12.10.5 Desitin Arzneimittel Recent Developments
12.11 Endo Pharmaceuticals
12.11.1 Endo Pharmaceuticals Company Information
12.11.2 Endo Pharmaceuticals Business Overview
12.11.3 Endo Pharmaceuticals Revenue in Parkinson Disease Drug Business (2020-2025)
12.11.4 Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio
12.11.5 Endo Pharmaceuticals Recent Developments
12.12 F.Hoffmann-La Roche
12.12.1 F.Hoffmann-La Roche Company Information
12.12.2 F.Hoffmann-La Roche Business Overview
12.12.3 F.Hoffmann-La Roche Revenue in Parkinson Disease Drug Business (2020-2025)
12.12.4 F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio
12.12.5 F.Hoffmann-La Roche Recent Developments
12.13 H.Lundbeck
12.13.1 H.Lundbeck Company Information
12.13.2 H.Lundbeck Business Overview
12.13.3 H.Lundbeck Revenue in Parkinson Disease Drug Business (2020-2025)
12.13.4 H.Lundbeck Parkinson Disease Drug Product Portfolio
12.13.5 H.Lundbeck Recent Developments
12.14 Valeant
12.14.1 Valeant Company Information
12.14.2 Valeant Business Overview
12.14.3 Valeant Revenue in Parkinson Disease Drug Business (2020-2025)
12.14.4 Valeant Parkinson Disease Drug Product Portfolio
12.14.5 Valeant Recent Developments
12.15 Apokyn
12.15.1 Apokyn Company Information
12.15.2 Apokyn Business Overview
12.15.3 Apokyn Revenue in Parkinson Disease Drug Business (2020-2025)
12.15.4 Apokyn Parkinson Disease Drug Product Portfolio
12.15.5 Apokyn Recent Developments
12.16 Orion
12.16.1 Orion Company Information
12.16.2 Orion Business Overview
12.16.3 Orion Revenue in Parkinson Disease Drug Business (2020-2025)
12.16.4 Orion Parkinson Disease Drug Product Portfolio
12.16.5 Orion Recent Developments
12.17 Stada Arzneimittel
12.17.1 Stada Arzneimittel Company Information
12.17.2 Stada Arzneimittel Business Overview
12.17.3 Stada Arzneimittel Revenue in Parkinson Disease Drug Business (2020-2025)
12.17.4 Stada Arzneimittel Parkinson Disease Drug Product Portfolio
12.17.5 Stada Arzneimittel Recent Developments
12.18 US WorldMeds
12.18.1 US WorldMeds Company Information
12.18.2 US WorldMeds Business Overview
12.18.3 US WorldMeds Revenue in Parkinson Disease Drug Business (2020-2025)
12.18.4 US WorldMeds Parkinson Disease Drug Product Portfolio
12.18.5 US WorldMeds Recent Developments
12.19 Bausch Health
12.19.1 Bausch Health Company Information
12.19.2 Bausch Health Business Overview
12.19.3 Bausch Health Revenue in Parkinson Disease Drug Business (2020-2025)
12.19.4 Bausch Health Parkinson Disease Drug Product Portfolio
12.19.5 Bausch Health Recent Developments
13 Report Conclusion
14 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings